Ascend Capital’s GSK GSK Stock Holding History

Ascend Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-322,417	Closed	-$17.2M	–	188
2014 Q4	$17.2M	Buy	322,417 +248,254	+335%	+$13.9M	0.66%	54
2014 Q3	$4.26M	Buy	+74,163	New	+$4.55M	0.13%	149

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ascend Capital's GSK Position: Q1 2015 in Review

Ascend Capital sold out of GSK (GSK) in Q1 2015, closing a stake of 322,417 shares — an estimated $17.2M sold.

Ascend Capital first reported a position in GSK in Q3 2014 and held it in 2 quarters. The position peaked at $17.2M in Q4 2014. 740 funds tracked by Wall St. Rank hold GSK as of Q1 2015.

Ascend Capital reported no remaining GSK position as of Q1 2015 after selling out during the quarter.
Ascend Capital sold 322,417 GSK shares in Q1 2015, an estimated $17.2M.
Ascend Capital first reported a position in GSK in Q3 2014 and held it in 2 quarters.
Ascend Capital's GSK position peaked at $17.2M in Q4 2014.
740 funds tracked by Wall St. Rank held GSK as of Q1 2015.

Based on Ascend Capital's 13F filing for Q1 2015, filed 14 May 2015.